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INTRODUCTION
Androgenetic alopecia (AGA) is a nonscarring alopecia that may represent an important psychosocial issue.[1] 
Despite being a very common condition drug therapies 
approved by the US Food and Drug Administration is 
limited to topical minoxidil and oral finasteride.[2] Efficacy 
of  these therapies is limited, and significant improvement 
is not always reached in all patients; therefore, there is an 
ongoing need towards finding new treatment options for 
this condition.[3,4]
Platelet‑rich plasma (PRP) is an autologous preparation 
of  platelets in concentrated plasma, usually containing 
a higher concentration of  platelets than the normal 
range (150,000–350,000 platelets/μL).[5,6] When platelet 
alpha‑granules become activated, they release numerous 
growth factors (GFs) which stimulate cell proliferation, 
differentiation, and angiogenesis.[3,6,7] PRP has been used 
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ABSTRACT
Background: Platelet-rich plasma (PRP) has emerged as a promising treatment for 
androgenetic alopecia (AGA). In spite of the several studies previously reported, to date, a 
standardized protocol for PRP preparation and application, as well as a standard method 
for evaluating results has not been established. Aims: The aim of this study is to propose 
a standardized method for preparation and application of PRP for male AGA (MAGA) 
and	 female	AGA	 (FAGA)	and	assess	 its	 safety	 and	efficacy	as	 a	 co-adjuvant	 therapy.	
Materials and Methods: Seventy-eight patients, 19 men and 59 women with AGA Grades 
II–IV	in	Ebling’s	scale,	currently	on	treatment	with	topical	minoxidil	and/or	oral	finasteride	
for more than a year without improvement, were included in this study. PRP was prepared 
using a single spin method, and injected in affected areas for 3 monthly sessions, followed 
by 3 bimonthly sessions. A decrease of at least one grade in Ebling’s scale was considered a 
successful result. Results: After the 6° session, 71.4% of MAGA and 73.4% of FAGA patients 
reached a successful outcome while 21.4% and 16.3%, respectively, remained without 
changes. Only 7.1% of MAGA and 10.2% of FAGA presented worsening of their condition. 
Conclusions: PRP together with a periodical application protocol can be considered effective 
as a coadjuvant therapy in patients who no longer respond to pharmacological treatments. 
Ebling’s scale was a practical and reliable parameter to allow a better evaluation in both 
MAGA and FAGA.
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in several fields of  medicine for multiple purposes such 
as wound healing, tissue regeneration, rejuvenation, 
and orthopedic grafts.[3,7‑9] In the field of  trichology, 
previous studies report that high concentrations of  GFs 
in PRP achieve the following effects: new hair growth, 
thickening of  preexisting hair shafts, proliferation of  
dermal papillae cells, and faster transition from telogen 
to anagen phase.[10‑12]
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With the exception of  the recent proposed protocols of  
PRP application in different fields of  dermatology by Alves 
et al. and Alves and Grimalt[7,13] as far as we are aware, there 
is still no general consensus about the dose, frequency and 
ways of  administration for PRP, as well as a reliable method 
for evaluating results. Therefore, clinical studies reported 
are difficult to compare due to high variability: small sample 
sizes, PRP treatment alone (not as a coadjuvant therapy), 
and short periods of  patients follow‑up. For all these 
reasons, our main objective is to propose a standardized 
method for preparation and application of  pure PRP for 
male AGA (MAGA) and female AGA (FAGA) and evaluate 
its efficacy as a coadjuvant therapy in patients who present 
an intermediate degree of  AGA. The method for evaluation 
of  improvement was Ebling’s scale, which is suitable to 
evaluate better both FAGA and MAGA.
MATERIALS AND METHODS
We conducted a prospective study that included 78 patients 
(19 men and 59 women), with an age range of  18–72 years. 
Exclusion criteria included coagulopathies, current 
treatment with anticoagulants, antiplatelet medications, 
or nonsteroidal anti‑inflammatory drugs, and pregnancy. 
Grading of  androgenic alopecia was assessed according 
to Ebling’s scale, ranging from form I to V. We selected 
this method of  evaluation since it is a reliable scale which 
can be easily assessed and can be applied in both men and 
women. Patients with Grades II–IV were selected for this 
study. All patients had been previously treated with topical 
5% minoxidil and/or daily oral finasteride (1 mg in men and 
5 mg in women) for at least 1 year without improvement. 
Intradermal injections of  autologous pure PRP (0.1 cc/cm2) 
in affected areas were administered in 3 monthly sessions, 
followed by 3 bimonthly sessions [Figure 1]. Finally, 
maintenance was achieved with 2–3 annual follow‑up 
sessions. Topical minoxidil and/or oral finasteride were not 
discontinued during PRP treatment. Follow‑up assessment 
was documented every 2 months through a global clinical 
picture under standardized conditions and trichoscopy 
photographs of  a previously determined area. A decrease 
in one grade of  Ebling’s scale was considered a successful 
result at any time of  the treatment.
Platelet‑rich plasma procedure
A peripheral blood sample of  18 cc was obtained from 
each patient in a 20 cc syringe previously loaded with 2 cc 
of  3.8% sodium citrate (anticoagulant). After obtaining 
a total of  20 cc of  anticoagulated blood, the content 
was transferred to a dedicate CE mark PRP tube and 
centrifuged using the equipment Omnigrafter® (Proteal, 
Barcelona, Spain): 1800 rpm, during 8 min, at 460‑gauge. 
Separation of  blood components into upper plasmatic 
portion with platelet‑poor plasma, lower plasmatic portion 
with PRP, and lower globular portion rich in leukocytes and 
erythrocytes was obtained. Then, 3 ml of  pure PRP were 
collected and platelets were activated adding 10% calcium 
chloride (CaCl2) in a proportion 0.05:1 mL (CaCl2:PRP) just 
before application. All steps were performed in a closed 
circuit which guaranteed a completely aseptic procedure.
RESULTS
From a total of  78 patients, 10 female and 5 male patients 
were lost to follow‑up. Sixty‑three patients concluded the 
study, 14 men and 49 women. After the 6° session of  
treatment, 10/14 (71.4%) of  MAGA and 36/49 (73.4%) 
of  FAGA patients showed successful improvement 
characterized by a decrease in at least one grade in Ebling’s 
scale [Figures 2‑5] while 3/14 (21.4%) of  MAGA and 
8/49 (16.3%) of  FAGA patients remained without changes. 
Worsening of  the condition was only seen in 1/14 (7.1%) 
of  MAGA and 5/49 (10.2%) of  FAGA patients.
By the evaluation of  global clinical and trichoscopy images, 
important changes such as the emergence of  new vellus 
hairs, as well as improvement of  hair quality, color, and 
width, were noted in the most cases [Figure 6].
DISCUSSION
In the field of  trichology, previous studies report that 
high concentrations of  GFs in PRP achieve the following 
effects: new hair growth, thickening of  preexisting 
hair shafts, proliferation of  dermal papillae cells, faster 
transition from telogen to anagen phase, and a reduction in 
the duration of  the hair cycle.[10] Other in vivo double‑blind 
studies have confirmed that GFs in PRP may also stimulate 
cellular differentiation and proliferation of  perifollicular 
collagen, fibroblasts, and blood vessels, generating a thicker 
epithelium that increases the hair cross‑section.[11]
Several signaling pathways have been proposed as the causal 
mechanisms for hair improvement after PRP treatment. 
Li et al. concluded that PRP increases proliferation of  
dermal papillae cells through stimulation of  protein kinase 
B (Akt) and extracellular regulated kinase (ERK) signaling 
pathways, which contribute to apoptosis and cell growth 
regulation, respectively.[5,6] Activated PRP also increases 
levels of  Bcl‑2, an anti‑apoptotic protein, and upregulates 
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β‑catenin, which promote a faster transition from telogen 
to anagen, and induce hair growth and follicular cell 
differentiation.[5,12]
AGA is a disorder with relevant hormonal and genetic 
influences, and since the latter cannot be changed, treatment 
is mainly focused toward hormonal blockage. Increased 
levels of  dihydrotestosterone (DHT), androgen receptors, 
and caspases generate cellular apoptosis and hair loss.[14] 
DHT plays a relevant role in the inhibition of  the hair 
follicle growth by inhibition of  adenylyl cyclase (AMP‑c), 
which results in shortening of  the anagen phase. All this 
mechanisms together result in the formation of  vellus or 
miniaturized hairs, and if  this stimulus persists, the hair 
may even disappear completely.[5]
Treatment of  AGA is essentially based on topical minoxidil 
and oral finasteride. Minoxidil prolongs the anagen phase 
through activation of  potassium channels,[15] increase 
of  prostaglandin E2 channels[8] and activation of  the 
extracellular pathways of  ERK and Akt.[16] All these actions 
result in an increased proliferation of  dermal papillae 
cells, as well as hair proliferation through an antiapoptotic 
effect by increasing the ratio of  Bcl/Bax.[9] Finasteride 
blocks caspases 1, 3, 8, and 9 and stimulates inhibitors of  
apoptosis (IAPs) such as X‑linked IAP, generating a longer 
anagen phase and increasing follicular hair growth.[17] GFs 
in PRP stimulate the growth of  existing miniaturized hair 
follicles, without interfering in the hormonal pathways 
of  AGA, thus, emphasizing the importance of  using a 
combined therapy to achieve optimal results.
Successful results have been reported in previous studies. 
Cervelli et al. selected 10 patients with MAGA that were not 
currently on any other medication for the past 12 months. 
Evaluation was randomized, blinded, with a placebo 
half‑head group, and evaluated by TrichoScan. After 
3 months, a mean increase of  27.7 hairs/cm2 was found in 
the treated areas, compared to 3 hairs/cm2 in the control 
areas.[15] Schiavone et al. studied 64 patients with MAGA and 
injected PRP enriched with leukocytes in two interventions 
separated by a 3‑month interval. Evaluation was conducted 
by two evaluators using the Jaeschke scale and by clinical 
photographs, one of  them stating improvement in all 
patients and the other in 62/64 patients.[18] Kang et al. used a 
CD34+ cell‑containing PRP preparation in 13 patients with 
AGA and placental extract preparation in a control group. 
They report an excellent improvement after 3 months of  
Figure 1: Infiltration of affected areas with the obtained pure 
platelet-rich plasma using five simultaneous 4 mm length mesotherapy 
needles and single needle
Figure 3: (a) A 51-year-old female with female androgenetic alopecia Ebling III, (b) excellent improvement at 3 months and (c) further improvement 
after 6 months, with a decrease of one grade in Ebling’s scale (Ebling II)
cba
Figure 2: (a) A 33-year-old male with male androgenetic alopecia 
Ebling II, (b) showing improvement after 3 sessions of treatment
ba
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treatment, with an increment in hair count of  20.5% ± 17%, 
and an increment in hair thickness of  31.3% ± 30.1%. 
They also evaluated a two‑point score using a formula that 
included different evaluations of  several points in the scalp, 
which also increased significantly after treatment.[19] Singhal 
et al. treated ten patients with AGA (Ludwig score I and II, 
and Hamilton–Norwood score 1–4) and administered PRP 
alone for 3 months, using a control group which was treated 
with medical treatment. Sessions of  PRP were administered 
every 2–3 weeks for 3 months. Evaluation by pull test showed 
significant results, reporting an improvement of  hair count, 
hair thickness, and alopecic degree.[20] More recently, Alves 
and Grimalt[13] reported a placebo‑controlled, double‑blind, 
half‑head study in 25 patients with AGA with Stages II–V of  
Hamilton–Norwood and I–III of  Ludwig, with no previous 
use of  any medication. Evaluation was conducted by 
Figure 6: (a) Trichoscopy images were taken of specific, representative areas, using FotoFinder®. In these pictures improvement of the hair 
quality, width and density can be observed after 3 and 10 months (b and c)
cba
Figure 5: (a) A 46-year-old female with female androgenetic alopecia Ebling IV, (b) notable improvement with decrease of one degree of Ebling 
at 3 months, and (c) further improvement at 6 months (decrease to Ebling II)
cba
Figure 4: (A) An 18-year-old female with frontal female androgenetic alopecia Ebling III, (B) showing a decrease in one grade of Ebling’s 
scale (Ebling II) after 3 sessions and (C) a decrease in two grades (Ebling I) after six sessions. Trichoscopy images (a-c) of the alopecic region 
taken with Fotofinder® showed improvement of hair density and width
cba
cba
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global photography and phototrichogram, and they report 
significant differences 6 months after the first PRP treatment, 
with an increase in mean anagen hairs (67.6 ± 13.1), 
telogen hairs (32.4 ± 13.1), hair density (179.9 ± 62.7), and 
terminal hair density (165.8 ± 56.8) when compared with 
baseline; though when compared to control group, the only 
significant value was an increase hair density. They propose 
application of  three initial treatments with 1 month apart, 
then wait 6 months, and perform another three cycles of  
PRP, with maintenance every 6 months or three cycles of  
PRP/year.[7]
All of  these studies demonstrate that improvement after 
PRP is evident, more commonly after the 3rd month. 
However, dose and administration protocols are not 
standardized, and neither are evaluation scales or methods, 
which in some cases were subjective and in some others 
complicated to assess in a daily practice basis.
CONCLUSIONS
After 6 years of  personal experience of  three of  the 
authors (JF, LB and EN) with application of  more than 
600 sessions of  pure PRP in more than 150 patients, we 
have found that our proposed method of  preparation, 
application, and periodicity of  PRP is effective since the 
third session. However, in this study we evaluated the results 
after the 6° course of  treatment to achieve solid results. 
We think that Ebling’s scale is a better standardized and 
useful evaluation tool, which can be easily and accurately 
used for evaluation of  AGA in both men and women. Our 
results state that more than 70% of  patients (MAGA and 
FAGA) achieved at least a decrease of  one grade in Ebling’s 
scale after the 6° session of  treatment. We support the 
idea that PRP could be used as a coadjuvant treatment and 
patients should not discontinue previous topical and/or 
oral medication since PRP does not suppress hormonal 
response in AGA and may therefore not be enough when 
used alone. PRP appeared to be more effective in FAGA 
than in MAGA, and the best results were obtained in frontal 
and parietal areas. There were no side effects observed in 
our series of  cases.
We strongly recommend the use of  PRP as a coadjuvant 
treatment in patients with AGA who are no longer 
responding to the standard pharmacological treatments.
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